Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06843148 Sponsor: Université de Sherbrooke Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT06843148
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 20 to 80 years
  • People who have been diagnosed with a liver condition called MASLD, which is defined as having fat in the liver combined with excess abdominal fat, measured using international guidelines specific to their country or ethnic background

Who may not be able to join:

  • People with significant liver scarring (fibrosis), detected by a special ultrasound scan, a calculated blood test score, or other signs of serious liver complications
  • People whose liver enzyme levels (ALT) in the blood are more than three times the normal upper limit
  • People who have another liver disease unrelated to MASLD
  • People with serious heart or kidney disease, most types of cancer, or other medical conditions that are not well controlled
  • People who have any reason they cannot safely have an MRI scan
  • People who have previously had a bad reaction or allergy to nicotinic acid (a form of vitamin B3)
  • People who have taken part in a research study involving radiation exposure within the two years before this trial starts
  • People who are allergic to eggs
  • People who smoke more than one cigarette per day, or who drink more than two alcoholic drinks per day
  • Women who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: André Carpentier, MD, Université de Sherbrooke

Phone: 1-819-346-1110

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Université de Sherbrooke
Registry
ClinicalTrials.gov
Start date
22 June 2026
Est. completion
1 March 2030

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Prolonged small-dose niacin treatment does not lead to desensitization of the niacin-induced reduction in hepatic total fatty acids flux.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov